Efficacy and safety of the S-1, nab-paclitaxel, and gemcitabine triplet regimen in patients with resected pancreatic ductal adenocarcinoma.

Front Oncol · 2025 · PMC12484532 · PMID 41040509

Europe PMC DOI

hedged sentence

0.0580

closest p · 1.2× alpha

0.0580

boldest claim

The sentences

showed a trendP = 0.058so close (0.05 < p ≤ 0.1)

CA19-9 level subgroup: In patients with CA19-9 ≥700 U/mL (experimental group, n = 8; control group, n = 7), the experimental group showed a trend toward longer median OS (22.3 months vs. 15.7 months, log-rank P = 0.058).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.